

## **Waverley Pharma Announces Collaboration with Dr. David E. Herbert and the University of Manitoba for the Development of a Synthetic Library of Chloroquine Analogs to Treat COVID-19**

WINNIPEG, June 25, 2020 /PRNewswire/ - Waverley Pharma Inc. ("Waverley Pharma" or the "Company") (TSXV:WAVE), an emerging Canadian pharmaceutical company, is pleased to announce it has entered into an Industrial Research Collaboration Agreement (the "Agreement") with the University of Manitoba to undertake a research and development project entitled "*Production of a Synthetic Library of Chloroquine Analogs and Precursors for Immediate and Future Development of COVID-19 Treatments.*" The funding for this project is provided by the Natural Sciences and Engineering Research Council of Canada (NSERC) under its Alliance COVID-19 Grants program.

Dr. David E. Herbert will serve as the Principal Investigator of the project. Dr. Herbert is currently an Associate Professor in the Department of Chemistry in addition to serving as the *Faculty of Science Research Chair in Fundamental Science (Physical Sciences)* at the University of Manitoba.

Waverley Pharma is granted exclusive worldwide intellectual property and commercial rights to any resulting products or technology developed under the Agreement in exchange for paying a royalty to the University of Manitoba on future sales of such products or technology.

### **About University of Manitoba, Faculty of Science**

At the Faculty of Science at the University of Manitoba, we take seriously our mission to produce the research scientists who invent a better future for us all, and to educate all those who pass through the University of Manitoba doors – the doctors, nurses, scientists, engineers, lawyers, accountants, entrepreneurs, CEOs, social scientists, artists, and educators. At the Faculty of Science we believe science is for everyone.

### **About NSERC**

NSERC aims to make Canada a country of discoverers and innovators for the benefit of all Canadians. The agency supports students in their advanced studies, promotes and supports discovery research, and fosters innovation by encouraging Canadian organizations to participate and invest in postsecondary research projects. NSERC researchers are on the vanguard of science, building on Canada's long tradition of scientific excellence.

### **About Waverley Pharma**

Waverley Pharma is an emerging pharmaceutical company focused on the development and commercialization of safe, effective and affordable cancer therapeutics in the EU and North American market. The Company, through its subsidiary, is selling two generic oncology products in the United Kingdom, namely capecitabine and temozolomide and has three additional generic

products under development. Waverley Pharma is committed to providing patients with affordable prescription medicines that lower healthcare costs and provide a better quality of life. For more information on Waverley Pharma please visit [www.waverleypharma.com](http://www.waverleypharma.com).

**Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.**

*Forward Looking Information: Statements contained in this press release that are not statements of historical fact, including, without limitation, statements containing the words "believes", "may", "plans", "will", "estimates", "continues", "anticipates", "intends", "expects" and similar expressions, may constitute "forward-looking information" within the meaning of applicable Canadian and U.S. federal securities laws (such forward-looking information and forward-looking statements are hereinafter collectively referred to as "forward-looking statements"). Forward-looking statements and other estimates, analysis and opinions of management of the Company made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factors which the Company believes to be relevant and reasonable in the circumstances. Inherent in forward-looking statements are known and unknown risks, uncertainties and other factors beyond the Company's ability to predict or control that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements, and as such, readers are cautioned not to place undue reliance on forward-looking statements. Such risk factors include, among others, the Company's potential product revenues, stage of development, additional capital requirements, risks associated with the completion and timing of clinical trials and obtaining regulatory approval to market the Company's products, the ability to protect its intellectual property, dependence upon collaborative partners, changes in government regulation or regulatory approval processes, and rapid technological change in the industry. Such statements are based on a number of assumptions which may prove to be incorrect, including, but not limited to, assumptions about: general business and economic conditions; the impact of changes in Canadian-US dollar and other foreign exchange rates on the Company's revenues, costs and results; the timing of the receipt of regulatory and governmental approvals for the Company's research and development projects; the availability of financing for the Company's commercial operations and/or research and development projects, or the availability of financing on reasonable terms; the uncertainties associated with the acceptance and demand for new products and market competition. The foregoing list of important factors and assumptions is not exhaustive. The Company undertakes no obligation to update publicly or otherwise revise any forward-looking statements or the foregoing list of factors, other than as may be required by applicable legislation. Additional discussion regarding the risks and uncertainties relating to the Company and its business can be found in the Company's other filings with the applicable Canadian securities regulatory authorities.*

For further information contact: Haaris Uddin, Chief Financial Officer by phone: 204-478-5609 or by E-mail: [huddin@waverleypharma.com](mailto:huddin@waverleypharma.com), or visit [www.waverleypharma.com](http://www.waverleypharma.com)

SOURCE Waverley Pharma Inc.